Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 106 member C (FAM106C) is a pseudogene affiliated with the long non-coding RNA (lncRNA) class and does not encode a functional protein or receptor [3][5][8]. It has been provisionally annotated in some resources as a "putative protein," but there is no experimentally validated protein product, and it is most accurately classified as a non-coding RNA/pseudogene [3][5][8]. Pseudogenes like FAM106C are often retained in the genome and may participate in regulatory RNA networks, potentially modulating the expression of other genes through RNA-based mechanisms such as acting as miRNA decoys or producing regulatory RNAs [4][8]. There is no evidence that FAM106C serves as a direct pharmacological or therapeutic target, nor as a biomarker, and no interacting drugs or established disease mechanisms involving this pseudogene have been reported [3][5][7][8]. In summary, FAM106C is not considered a druggable target or functional molecule in therapeutic contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 106 member C (FAM106C).